Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.

Kittisak TangchitpianvitEkarat RattarittamrongChatree Chai-AdisaksophaPokpong PiriyakhuntornThanawat RattanathammetheeSasinee HantrakoolAdisak TantiworawitLalita Norasetthada

Published in: Hematology (Amsterdam, Netherlands) (2021)

There was no significant difference in the one-year RFS and OS between IDAC and HiDAC. The IDAC regimen is an acceptable option for consolidation treatment in AML.

Keyphrases

high dose
acute myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
low dose
prognostic factors
stem cells
allogeneic hematopoietic stem cell transplantation
mesenchymal stem cells
combination therapy
patient reported
cell therapy